Tessa Therapeutics' 'Off-the-Shelf' CAR-T Therapy Shows Promising Results in Early-Stage Study of Hodgkin Lymphoma, Business News
Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows Promising Results in Early-Stage Study of Hodgkin Lymphoma GlobeNewswire June 16, 2023 78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapySafety data encouraging with no graft-versus-host-disease and no neurotoxicityUpdated data highlighted in podium presentation at the 17th...
Source: asiaone.com